Proactive Investors
13 Nov 2025, 14:16 UTC · 51w ago
Immunic advances MS program with key clinical findings in Q3
Impact · against what's priced in
Immunic is a net positive following strong Phase 2 CALLIPER data in progressive MS and extended patent protection to 2041. However, these clinical gains are partially offset by a looming cash crunch that will necessitate dilutive financing within the next 12 months.
- IMUX+0.40
No priced-in read yet
- In context
The Phase 2 CALLIPER trial's two-fold probability of disability improvement in progressive MS provides a strong clinical catalyst for a lead asset in an underserved market. While the 2041 patent extension is positive, the reported $35.1 million cash balance necessitates near-term capital raises, creating a headwind of potential dilution.
Read from the article alone
Search tags
